Alison Kodjak

Alison Fitzgerald Kodjak is a health policy correspondent on NPR's Science Desk.

Her work focuses on the business and politics of health care and how those forces flow through to the general public. Her stories about drug prices, limits on insurance and changes in Medicare and Medicaid appear on NPR's shows and in the Shots blog.

She joined NPR in September 2015 after a nearly two-decade career in print journalism, where she won several awards—including three George Polk Awards—as an economics, finance, and investigative reporter.

She spent two years at the Center for Public Integrity, leading projects in financial, telecom, and political reporting. Her first project at the Center, "After the Meltdown," was honored with the 2014 Polk Award for business reporting and the Society of Professional Journalists Sigma Delta Chi award.

Her work as both reporter and editor on the foreclosure crisis in Florida, on Warren Buffet's predatory mobile home businesses, and on the telecom industry were honored by several journalism organizations. She was part of the International Consortium of Investigative Journalists team that won the 2015 Polk Award for revealing offshore banking practices.

Prior to joining the Center, Alison spent more than a decade at Bloomberg News, where she wrote about the convergence of politics, government, and economics. She interviewed chairmen of the Federal Reserve and traveled the world with two U.S. Treasury secretaries.

And as part of Bloomberg's investigative team she wrote about the bankruptcy of General Motors Corp. and the 2010 Gulf Oil Spill. She was part of a team at Bloomberg that successfully sued the Federal Reserve to release records of the 2008 bank bailouts, an effort that was honored with the 2009 George Polk Award. Her work on the international food price crisis in 2008 won her the Overseas Press Club's Malcolm Forbes Award.

Fitzgerald Kodjak and co-author Stanley Reed are authors of In Too Deep: BP and the Drilling Race that Took It Down, published in 2011 by John Wiley & Sons.

She's a graduate of Georgetown University and Northwestern University's Medill School of Journalism.

She raises children and chickens in suburban Maryland.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

ARI SHAPIRO, HOST:

Updated 11:16 EDT: This story now includes information about the Food and Drug Administration's release of a list of complaints against brand-name drugmakers for hindering access to samples for generic testing.

When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month's supply.

Health and Human Services Secretary Alex Azar has this pen. It's not all that remarkable looking, but he held it up multiple times Monday at a briefing with reporters.

"This pen," he said, "has a lot of power."

And he said he is prepared to use it.

Azar was making the point that in the area of drug prices, the head of HHS — which runs the Medicare and Medicaid programs and buys about $130 billion in prescription drugs each year — can make a lot of changes in the pharmaceutical market. And he doesn't need congressional approval to do it.

President Trump presented a broad-brush outline of how his administration hopes to stem the decades-long increase in prescription drug prices and spending, in a speech Friday in the Rose Garden of the White House.

The administration also released a 39-page document describing a variety of proposals it is either considering or studying in an effort to lower costs to individuals, corporations, the government and the economy as a whole.

A few months ago, I wrote a check for $12,000 but couldn't figure out exactly why.

The payment was to secure a place for my mother at Sligo Creek Center, in Takoma Park, Md. It's a nursing home and rehab center owned by Genesis Healthcare.

My mother was about to be discharged from Holy Cross Hospital, in nearby Silver Spring, after a fall. Medicare wouldn't pay for her rehabilitation care.

Pages